Recent studies have shown that POLQ is significantly up-regulated in hepatocellular carcinoma, lung cancer, breast cancer, ovarian cancer, prostate cancer and other malignant tumors, and is closely related to poor clinical outcomes of patients [6–10]. This evidence concerns the gene POLQ and hepatocellular carcinoma.